BR112022012198A2 - Anticorpo antiproperdina, composição, imunoconjugado, molécula biespecífica, sequência de ácido nucleico, vetor de expressão, célula hospedeira e combinação - Google Patents

Anticorpo antiproperdina, composição, imunoconjugado, molécula biespecífica, sequência de ácido nucleico, vetor de expressão, célula hospedeira e combinação

Info

Publication number
BR112022012198A2
BR112022012198A2 BR112022012198A BR112022012198A BR112022012198A2 BR 112022012198 A2 BR112022012198 A2 BR 112022012198A2 BR 112022012198 A BR112022012198 A BR 112022012198A BR 112022012198 A BR112022012198 A BR 112022012198A BR 112022012198 A2 BR112022012198 A2 BR 112022012198A2
Authority
BR
Brazil
Prior art keywords
antibody
present
acid sequence
antiproperdine
immunoconjugate
Prior art date
Application number
BR112022012198A
Other languages
English (en)
Inventor
Kumar Mendiratta Sanjeev
Singh Arun
Kasera Ramkrashan
Parikh Aashini
Upadhyay Jimit
KALITA Pankaj
Bandyopadhyay Dilip
Shah Ashu
Original Assignee
Zydus Lifesciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zydus Lifesciences Ltd filed Critical Zydus Lifesciences Ltd
Publication of BR112022012198A2 publication Critical patent/BR112022012198A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ANTICORPO ANTIPROPERDINA, COMPOSIÇÃO, IMUNOCONJUGADO, MOLÉCULA BIESPECÍFICA, SEQUÊNCIA DE ÁCIDO NUCLEICO, VETOR DE EXPRESSÃO, CÉLULA HOSPEDEIRA E COMBINAÇÃO. A presente invenção proporciona um anticorpo, ou porção de ligação a antígeno do mesmo, que pode se ligar a properdina (fator P). O anticorpo da presente invenção conduz a inibição seletiva de via alternativa do complemento ao mesmo tempo em que permite que as vias clássicas e de lectina continuem. Além disso o anticorpo da presente invenção pode ter ligação modificada ou reduzida a Fc¿Rs para minimizar a sua atividade ADCC. A presente invenção proporciona um anticorpo que compreende uma sequência de amino ácidos para minimizar a sua atividade CDC. O anticorpo de acordo com a presente invenção tem afinidade superior de ligação a FcRn e, portanto, o anticorpo de acordo com a presente invenção pode ter meia-vida de circulação longa no corpo do paciente e o mesmo pode ser administrado em uma frequência de dosagem reduzida. O anticorpo de acordo com a presente invenção pode adicionalmente ser usado na preparação de um fármaco para tratar doenças através da inibição da via alternativa do complemento.
BR112022012198A 2020-01-08 2021-01-08 Anticorpo antiproperdina, composição, imunoconjugado, molécula biespecífica, sequência de ácido nucleico, vetor de expressão, célula hospedeira e combinação BR112022012198A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202021000807 2020-01-08
PCT/IB2021/050115 WO2021140475A1 (en) 2020-01-08 2021-01-08 Anti-properdin antibodies and preparation thereof

Publications (1)

Publication Number Publication Date
BR112022012198A2 true BR112022012198A2 (pt) 2022-09-06

Family

ID=76788052

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012198A BR112022012198A2 (pt) 2020-01-08 2021-01-08 Anticorpo antiproperdina, composição, imunoconjugado, molécula biespecífica, sequência de ácido nucleico, vetor de expressão, célula hospedeira e combinação

Country Status (7)

Country Link
US (1) US20230054202A1 (pt)
EP (1) EP4087869A4 (pt)
JP (1) JP2023510769A (pt)
CN (1) CN115003694A (pt)
BR (1) BR112022012198A2 (pt)
MX (1) MX2022008380A (pt)
WO (1) WO2021140475A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
AU2008351988B2 (en) * 2008-03-03 2013-07-25 Novelmed Therapeutics, Inc. Anti-properdin antibodies
AU2011223660B2 (en) * 2010-03-02 2016-10-13 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit C5 interactions with properdin
EP2545075B1 (en) * 2010-03-10 2020-07-01 NovelMed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
EP2726103B1 (en) * 2011-07-01 2018-09-05 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
KR102613874B1 (ko) * 2017-01-30 2023-12-15 알렉시온 파마슈티칼스, 인코포레이티드 1가 항-프로페르딘 항체 및 항체 단편

Also Published As

Publication number Publication date
CN115003694A (zh) 2022-09-02
EP4087869A4 (en) 2024-03-06
US20230054202A1 (en) 2023-02-23
JP2023510769A (ja) 2023-03-15
MX2022008380A (es) 2022-08-04
WO2021140475A1 (en) 2021-07-15
EP4087869A1 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
Lundbäck et al. A novel high mobility group box 1 neutralizing chimeric antibody attenuates drug‐induced liver injury and postinjury inflammation in mice
Seizer et al. Extracellular cyclophilin A activates platelets via EMMPRIN (CD147) and PI3K/Akt signaling, which promotes platelet adhesion and thrombus formation in vitro and in vivo
Junghans et al. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.
Petreaca et al. Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability
Duan et al. Mdivi-1 attenuates oxidative stress and exerts vascular protection in ischemic/hypoxic injury by a mechanism independent of Drp1 GTPase activity
JP7008920B2 (ja) 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用
BRPI0417429A (pt) anticorpo monoclonal isolado ou uma porção de ligação de antìgeno deste, composição, imunoconjugado, molécula biespecìfica, vetor de expressão, célula hospedeira, camundongo transgênico, hibridoma, e, métodos de inibir uma resposta inflamatória ou autoimune, de tratar uma doença inflamatória ou autoimune, de tratar uma infecção viral ou bacteriana e de preparar um anticorpo anti-ip-10
Burness Idarucizumab: first global approval
BRPI0610235B8 (pt) anticorpos monoclonais geneticamente modificados e diferentes daqueles encontrados na natureza, ou porção de ligação ao antígeno dos mesmos, usos terapêuticos dos mesmos, composições, imunoconjugado, molécula biespecífica compreendendo os mesmos, molécula de ácido nucléico e vetor de expressão
BR112012022044A2 (pt) ''anticorpo,imunoconjugado,formulação farmacêutica,uso do anticorpo,método de tratamento,anticorpo biespecifico isolado e célula hospedeira''.
BR0315295A (pt) Anticorpo, hibridoma, transfectoma, célula hospedeira, eucariótica ou procariótica, animal não humano ou planta transgênicos, composição, imunoconjugado, molécula biespecìfica, kit, vetor de expressão e métodos de produzir um anticorpo monoclonal humano, de inibir o crescimento de uma célula que expressa cd20, de matar uma célula que expressa cd20, de tratar ou prevenir uma doença e de detectar a presença de antìgeno de cd20 ou uma célula que expressa cd20 em uma amostra e antìgeno de cd20 ou uma célula que expressa cd20 em um paciente
MX2014009706A (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
JP2022525164A (ja) 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用
Chuderland et al. The role of pigment epithelium-derived factor in the pathophysiology and treatment of ovarian hyperstimulation syndrome in mice
Moreno Ayala et al. Humanin promotes tumor progression in experimental triple negative breast cancer
ES2923677T3 (es) Novedosos anticuerpos anti-GPVI humanos y usos de los mismos
US9545433B2 (en) Myonectin (CTRP15), compositions comprising same, and methods of use
US10835575B2 (en) Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA)
CA3028586A1 (en) Wnt inhibitors for use in the treatment of fibrosis
CN105916523A (zh) 针对成纤维细胞生长因子受体-3(fgfr3)的化合物和治疗方法
JP2012507003A (ja) チトクロームｃアセチル化の検出及び調節
Kuznik et al. Development of a benzothiazole scaffold-based androgen receptor N-terminal inhibitor for treating androgen-responsive prostate cancer
BR112022012198A2 (pt) Anticorpo antiproperdina, composição, imunoconjugado, molécula biespecífica, sequência de ácido nucleico, vetor de expressão, célula hospedeira e combinação
Pidala et al. Ixazomib for treatment of refractory chronic graft-versus-host disease: a chronic GVHD consortium phase II trial
ATE278017T1 (de) Humaner k+ ionenkanal und therapeutische verwendungen davon